<DOC>
	<DOCNO>NCT00003591</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy plus paclitaxel treating patient nonmetastatic , unresectable pancreatic cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Paclitaxel Treating Patients With Nonmetastatic , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient nonmetastatic , unresectable pancreatic cancer receive external beam irradiation weekly paclitaxel . II . Determine median survival treatment patient . III . Evaluate acute late treatment morbidity paclitaxel patient . IV . Correlate p53 status treatment response treatment patient population . OUTLINE : This open label , multicenter study . Patients highly recommend undergo laparoscopic surgical staging prior protocol exclude peritoneal hepatic metastasis . Patients receive paclitaxel IV 3 hour weekly 6 week begin day 1 follow 1.5 hour later external beam radiotherapy daily 5 day week 5.5 week begin day 1 . All patient restaged abdominal CT scan 6 week follow completion chemoradiotherapy . If mark response treatment time , curative surgery may attempt discretion attend surgeon . Patients follow every 3 month 1 year , every 4 month second year , every 6 month year 3-5 , annually thereafter . PROJECTED ACCRUAL : A total 100 patient accrue study 12 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmetastatic , unresectable pancreatic adenocarcinoma No evidence metastatic disease major viscera peritoneal seed Residual disease resection ( R1 2 micro macroscopic residual ) eligible measurable disease post operative CT MRI scan Recurrent disease follow radical surgery eligible All malignant disease must encompassable within single irradiation field Must radiographically assessable disease CT 5 mm cut spiral CT PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,800/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL Biliary system stented Renal : Creatinine le 3.0 mg/dL OR Creatinine clearance least 40 mL/min Other : If patient biliary gastroduodenal obstruction , must drainage prior start chemoradiation Oral intake least 1,500 calorie per day No significant infection coexistent medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior paclitaxel At least 4 week since prior gemcitabine No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy plan field Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>